Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

PURPOSE: Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we describe the patterns and time course of respons...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Surg Oncol
Main Authors: Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2016
Assuntos:
Melanomas
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5090012/
https://ncbi.nlm.nih.gov/pubmed/27342831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-016-5286-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados